Trial Profile
A Phase I, First-in-Human, Randomized, Double-Blind, Placebo-Controlled Trial of Single and Multiple Ascending Doses of M5717 to Assess the Safety, Tolerability and Pharmacokinetic Profile of Oral Doses, and to Assess the Antimalarial Activity of M5717 Against Plasmodium Falciparum in Healthy Male and Female Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Cabamiquine (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Merck KGaA
- 01 Dec 2021 Results published in The Lancet Infectious Diseases
- 18 Jun 2019 Status changed from recruiting to completed.
- 04 Mar 2019 Planned number of patients changed from 80 to 112.